

PHAYM001: Preparation for professional practice

[View Online](#)

[1]

Antipsychotics increase mortality in elderly patients with dementia:
http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php.

[2]

Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC):
<http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>.

[3]

Bhasin, M. et al. 2007. Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. *International Journal of Geriatric Psychiatry*. 22, 9 (Sep. 2007), 890–895. DOI:<https://doi.org/10.1002/gps.1759>.

[4]

British National Formulary: <http://www.bnf.org/bnf/index.htm>.

[5]

Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University: <http://centreformedicinesoptimisation.co.uk/mtrac/>.

[6]

Chronic obstructive pulmonary disease:
<http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>.

[7]

Clinical guidelines, CG42 - Issued: November 2006: <http://guidance.nice.org.uk/CG42>.

[8]

Commissioners and healthcare professionals - Training videos:
http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/.

[9]

Complete Guide to Behavioural and Psychological symptoms of Dementia:
<http://www.ipa-online.org/>.

[10]

CPPE - Centre for Pharmacy Postgraduate Education: <https://www.cppe.ac.uk/>.

[11]

DH Living well with dementia: a National Dementia Strategy:
<https://www.gov.uk/government/organisations/department-of-health>.

[12]

Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC):
<http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbixa+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>.

[13]

Electronic Medicines Compendium (eMC): <http://www.medicines.org.uk/emc/>.

[14]

Electronic Medicines Compendium (eMC): <http://www.medicines.org.uk/emc/>.

[15]

Electronic Medicines Compendium (eMC): <https://www.medicines.org.uk/emc/>.

[16]

Evidence Search - Search Engine for Evidence in Health and Social Care:
<https://www.evidence.nhs.uk/>.

[17]

Evidence Search - Search Engine for Evidence in Health and Social Care:
<https://www.evidence.nhs.uk/>.

[18]

Evidence Search - Search Engine for Evidence in Health and Social Care:
<https://www.evidence.nhs.uk/>.

[19]

Exelon - Summary of Product Characteristics (SPC) - (eMC):
<https://www.medicines.org.uk/emc/search?q=Exelon+>.

[20]

GOV.UK: <https://www.gov.uk/government/organisations/department-of-health>.

[21]

Greene, R.J. and Harris, N.D. 2008. Pathology and therapeutics for pharmacists: a basis for

clinical pharmacy practice. Pharmaceutical Press.

[22]

Heart failure - chronic: <http://cks.nice.org.uk/heart-failure-chronic>.

[23]

Hubley, J. et al. 2013. Practical health promotion. Polity Press.

[24]

Kavirajan, H. and Schneider, L.S. 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. *The Lancet Neurology*. 6, 9 (Sep. 2007), 782–792.
DOI:[https://doi.org/10.1016/S1474-4422\(07\)70195-3](https://doi.org/10.1016/S1474-4422(07)70195-3).

[25]

Kumar, P.J. and Clark, M.L. 2012. Kumar & Clark's clinical medicine. Saunders Elsevier.

[26]

Laverack, G. 2007. Health promotion practice: building empowered communities. Open University Press.

[27]

Macdowall, W. et al. 2006. Health promotion practice. Open University Press.

[28]

Maher, A.R. et al. 2011. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. *JAMA*. 306, 12 (Sep. 2011).
DOI:<https://doi.org/10.1001/jama.2011.1360>.

[29]

Maher, A.R. 2011. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association. 306, 12 (Sep. 2011). DOI:<https://doi.org/10.1001/jama.2011.1360>.

[30]

Map of Medicine | Home: <http://www.mapofmedicine.com/>.

[31]

Martinón-Torres, G. et al. 2004. Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews. (Jul. 2004). DOI:<https://doi.org/10.1002/14651858.CD004990>.

[32]

Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care: <https://www.evidence.nhs.uk/>.

[33]

Miller, W.R. and Rollnick, S. 2013. Motivational interviewing: helping people change. Guilford Press.

[34]

National Institute for Health and Care Excellence: <http://www.nice.org.uk/>.

[35]

NHS Health Check - NHS Choices:
<http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>.

[36]

NICE Clinical Knowledge Summaries (CKS): <http://cks.nice.org.uk/>.

[37]

NPC | National Prescribing Centre: <https://www.guidelinesinpractice.co.uk>.

[38]

NPC | National Prescribing Centre: <https://www.guidelinesinpractice.co.uk>.

[39]

Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide: <https://www.alzheimers.org.uk/bpsdguide>.

[40]

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. 1998. Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. 155, 1 (1998), 54-61. DOI:<https://doi.org/10.1176/ajp.155.1.54>.

[41]

Prochaska, J.O. et al. 1994. Changing for good. William Morrow.

[42]

Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC): .

[43]

Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC): <http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>.

[44]

Rollnick, S. et al. 1999. Health behavior change: a guide for practitioners. Churchill Livingstone.

[45]

Rollnick, S. et al. 2008. Motivational interviewing in health care: helping patients change behavior. Guilford Press.

[46]

Royal Pharmaceutical Society (RPS): <http://www.rpharms.com/home/home.asp>.

[47]

Scottish Intercollegiate Guidelines Network (SIGN): <http://www.sign.ac.uk/>.

[48]

Sube Banerjee 12AD. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services.

[49]

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format): <http://guidance.nice.org.uk/TA217/Guidance/doc/English>.

[50]

Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges: <http://www.kmpt.nhs.uk/policies>.

[51]

Waldemar, G. et al. 2008. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 23, 9 (Sep. 2008), 979–981. DOI:<https://doi.org/10.1002/gps.1979>.

[52]

Walker, R. and Whittlesea, C. 2012. *Clinical pharmacy and therapeutics*. Churchill Livingstone.

[53]

Warner, J. and Smith, T. The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? *The rise and fall of antipsychotic prescribing in dementia*. 14, 2, 24–27.

[54]

Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE.

[55]

Medicines Use Review and Prescription Intervention service.

[56]

Service specification - New Medicine Service (NMS).